GlobeNewswire PharmaceuticalsCodex · 实盘不做把握 8/10
北京时间·🕒 发布 21:38:00时区推断·⟳ 抓取 21:40:56·⚡ 决策 07-30 21:42:20 +1m24s·88.9 天前
赛诺菲发布2026年半年度财务报告可获取及备案通知
本条仅通知半年度财务报告已上线并向AMF/SEC备案，正文未披露收入、利润、指引或临床/商业化新增信息。
📄 原文GlobeNewswire Pharmaceuticals↗ 原文
Press Release: Sanofi’s half-year financial report for 2026
Sanofi’s half-year financial report for 2026 Paris, July 30, 2026. Sanofi announces that its half-year financial report…
不做 赛诺菲（SNY.US）
例行半年度财务报告可获取及备案通知，正文无业绩超预期、指引调整或其它明确方向内容，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 low · price-in 风险 medium ↗
关键理由
- 本条仅通知半年度财务报告已上线并向AMF/SEC备案，正文未披露收入、利润、指引或临床/商业化新增信息。
主要风险
- 若随后出现含超预期财务数据或指引变化的独立财报解读，应由新信号重新研判。
原文全文
展开原文 · 1,857 字
Sanofi’s half-year financial report for 2026
Paris, July 30, 2026. Sanofi announces that its half-year financial report for the period ending June 30, 2026, is now available online and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the US Securities and Exchange Commission (SEC) under form 6-K.
This document may be found on www.sanofi.com and downloaded from the “Investors” page, under the heading “Financial Reports and Other Publications”.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Laura Romby| + 33 6 74 16 74 29 | laura.romby@sanofi.com
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 |thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | + 1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com
Attachment
Paris, July 30, 2026. Sanofi announces that its half-year financial report for the period ending June 30, 2026, is now available online and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the US Securities and Exchange Commission (SEC) under form 6-K.
This document may be found on www.sanofi.com and downloaded from the “Investors” page, under the heading “Financial Reports and Other Publications”.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Laura Romby| + 33 6 74 16 74 29 | laura.romby@sanofi.com
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 |thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | + 1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com
Attachment
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。